Information Provided By: 
Fly News Breaks for April 4, 2016
TXMD
Apr 4, 2016 | 05:49 EDT
Goldman Sachs analyst Jay Olson started TherapeuticsMD with a Buy rating and $10 price target. With the stock down 40% since the end of December, the analyst believes TherapeuticsMD has been unfairly classified as a biopharma. He views the company's market opportunity as more consumer-like and thinks the stock will return to prior levels.
News For TXMD From the Last 2 Days
There are no results for your query TXMD
